Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Equity Income (2022 - 2024)

Crinetics Pharmaceuticals has reported Equity Income over the past 3 years, most recently at -$470000.0 for Q1 2024.

  • Quarterly results put Equity Income at -$470000.0 for Q1 2024, changed N/A from a year ago — trailing twelve months through Dec 2024 was -$470000.0 (up 90.96% YoY), and the annual figure for FY2024 was -$470000.0, up 90.96%.
  • Equity Income for Q1 2024 was -$470000.0 at Crinetics Pharmaceuticals, up from -$4.2 million in the prior quarter.
  • Over the last five years, Equity Income for CRNX hit a ceiling of -$470000.0 in Q1 2024 and a floor of -$4.2 million in Q4 2023.
  • Median Equity Income over the past 3 years was -$1.0 million (2022), compared with a mean of -$1.7 million.